EMERYVILLE, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Bionovo, Inc. will participate in Bank of Montreal’s Focus on Healthcare Conference taking place on December 6 - 7, 2006, at the Millennium Broadway Hotel. Bionovo’s management will present on Wednesday, December 6, at 10:00 a.m. EST. Additional information regarding the conference can be found at http://www.bmocm.com/conferences/healthcare2006/default.asp .
To access a live audio webcast, log on to www.bionovo.com. Please connect to Bionovo’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.
About Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The Company has two drugs in clinical testing. MF101 for the treatment of vasomotor symptoms (hot flashes) associated with menopause is currently in Phase 2 and Phase 1 testing has been completed for BZL101 for the treatment of advanced breast cancer. The Company is developing its products in close collaboration with leading U.S. academic research centers including the University of California, San Francisco; University of Colorado Health Sciences Center; University of California, Berkeley; and University of Texas, Southwestern. For further information please visit: www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated, or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission SEC), which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer of BioNovo, Inc.,+1-510-601-2000, or jim@bionovo.com; or media, Jennifer Larson,+1-415-409-2729, or jlarson@labfive.com; or investors, Antima “Taz"Sadhukhan of Investor Relations Group, +1-212-825-3210, both for Bionovo,Inc.
Web site: http://www.bionovo.com/
